Biosimilars Advisory Service

September 2013

Biosimilars Advisory Service: Physician Perspectives On Pegylated IFN And TNF-a Inhibitors In Immune And Infectious Diseases

Introduction:

Rheumatologists and gastroenterologists will be the first specialists in the United States and Europe who will have the opportunity to prescribe biosimilar monoclonal antibodies, such as infliximab. However, these specialists have, so far, had little first-hand experience with biosimilars. Understanding their familiarity with and perceptions of biosimilars is critical in determining how to position biosimilars in the immunology and infectious disease markets as well as for building a defense strategy against the imminent threat of biosimilars competition. We conducted primary market research with rheumatologists and gastroenterologists in the United States and Europe to understand their perspectives on biosimilars and their expected adoption rates. Based on our extensive market research, this report also provides highly granular, brand and biosimilar market forecasts for the United States, Europe, and Japan.
This immune and infectious diseases report is part of the Biosimilars Advisory Service. The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. Quarterly webinars detailing major developments, analyst insight addressing key market changes, therapeutic-area-specific primary research and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on BioTrends to keep you up-to-date on the biosimilars landscape and poised to maximize opportunities for your business.

Questions Answered in This Report:

  *   Understand gastroenterologists’ and rheumatologists’ attitude towards biosimilars
- How aware are gastroenterologists and rheumatologists with biosimilars?
- How similar are biosimilars and brands according to both of these specialists?
- What are the greatest hurdles for uptake of biosimilar versions of these agents?
- What level of clinical trial data will convince gastroenterologists and rheumatologists that biosimilars and brands are comparable?
- What are physician opinions on indication extrapolation and pharmacy-level substitution?

  *   Understand how gastroenterologists’ and rheumatologists’ attitudes translate to expected use of biosimilars
- How quickly do gastroenterologists and rheumatologists expect to adopt biosimilars?
- How will price affect gastroenterologists’ and rheumatologists’ uptake of biosimilars?
- To what extent will cross brand erosion from biosimilars occur?

  *   Learn about the forecast for the anticipated uptake of biosimilar versions of TNF-? inhibitors and other biologics for immune diseases
- What is the expected patient share of biosimilar versions of major biologics prescribed in immunology and infectious diseases?
- At what price discounts will biosimilars for different brands enter the market, and how might this change?
- What is the annualized commercial potential for biosimilar versions of major biologics prescribed in immunology and infectious diseases?
- Will biosimilars steal a majority or minority of the market share?

Scope:

Sample Frame & Methodology:

- This report is based on a quantitative survey of 91 rheumatologists and 94 gastroenterologists in the United States, France, and Germany.

- Markets covered: United States, Europe, and Japan

- Primary research: Quantitative 45-minute online survey of 91 rheumatologists and 94 gastroenterologists from the United States, France, and Germany.

- Quantitative online 45 minute survey of 94 gastroenterologists and 91 rheumatologists from the United States, France, and Germany

To qualify, respondents must meet the following criteria:

- Have worked in clinical practice for a minimum of 3 years and a maximum of 30 yea

- Work for a community hospital, private practice, or academic hospital (defined as having a large teaching facility).

- Spend more than 50% of their professional time in clinical practice if associated with an academic hospital or 75% of their professional time if based at a community hospital or private practice.

- Be familiar with the major biologic agents used in the treatment of immune diseases or hepatitis C virus.

Deliverables:

- Final report in .ppt and .pdf format

- Live webinars highlighting key findings of the report and survey results

- Detailed market forecasts at the brand and biosimilar level, split by U.S., EU5 and Japan in .xls format

- Proprietary question slide decks and frequency tables

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each therapy area

Related 2013 Reports:

- Acceptance of Biosimilars Across Physician Specialties

- Biosimilars Advisory Service: Corporate Strategies

- Biosimilars Advisory Service: Global Pipelines, Pathways, and Key Stakeholder Perceptions

- Biosimilars Advisory Service: Overall Physicians

- Biosimilars Advisory Service: US and EU Payer Perspectives

- Biosimilars Advisory Service: Endocrinology and Nephrology

- Biosimilars Advisory Service: Oncology

Key Terms for This Report:

- Biologic

- Biosimilar

- Biobetter

- Market access

- Pricing

- Reimbursement

- Rheumatology

- Gastroenterology

- Indication extrapolation

- Automatic substitution

Search Published Reports


Decision Resources Group brands include: